Short Bowel Syndrome - Pipeline Review, H1 2018

Publisher Name :
Date: 12-Jun-2018
No. of pages: 59
Inquire Before Buying

Short Bowel Syndrome - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2018, provides an overview of the Short Bowel Syndrome (Gastrointestinal) pipeline landscape.

Short bowel syndrome is a complex disease that occurs due to the physical loss or the loss of function of a portion of the small and/or large intestine. Symptoms include bloating, cramping, fatigue, heartburn, vomiting, weakness and diarrhea. Complications of short bowel syndrome include malnutrition, peptic ulcers, kidney stones and small intestinal bacterial overgrowth. Treatment includes vitamin and mineral supplements, antibiotics, proton pump inhibitors and bile-salt binders.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Short Bowel Syndrome - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Short Bowel Syndrome (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Short Bowel Syndrome (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Short Bowel Syndrome and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, IND/CTA Filed and Preclinical stages are 2, 2, 2 and 7 respectively.

Short Bowel Syndrome (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Short Bowel Syndrome (Gastrointestinal).

- The pipeline guide reviews pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Short Bowel Syndrome (Gastrointestinal) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Short Bowel Syndrome (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Short Bowel Syndrome (Gastrointestinal)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Short Bowel Syndrome (Gastrointestinal).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Short Bowel Syndrome (Gastrointestinal) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Short Bowel Syndrome - Pipeline Review, H1 2018

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Short Bowel Syndrome - Overview
Short Bowel Syndrome - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Short Bowel Syndrome - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Short Bowel Syndrome - Companies Involved in Therapeutics Development
Adocia SAS
Ardelyx Inc
Hanmi Pharmaceuticals Co Ltd
Naia Ltd
Nutrinia Ltd
OxThera AB
Sancilio & Company Inc
Shire Plc
Tasly Pharmaceutical Group Co Ltd
Zealand Pharma AS
Short Bowel Syndrome - Drug Profiles
exenatide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
FE-203799 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glepaglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GXG-8 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-15912 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melatonin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NB-1002 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NTRA-9620 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Oxabact - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RDX-8940 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SC-403 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
teduglutide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Short Bowel Syndrome - Dormant Projects
Short Bowel Syndrome - Discontinued Products
Short Bowel Syndrome - Product Development Milestones
Featured News & Press Releases
May 31, 2018: Zealand Pharma to present new clinical Phase 2 results on glepaglutide for the treatment of short bowel syndrome at the DDW conference in the U.S.
Apr 26, 2018: Zealand announces successful End-of-Phase 2 meeting with FDA on glepaglutide for short bowel syndrome
Apr 09, 2018: Revestive is accepted for restricted use within NHS Scotland
Jan 23, 2018: New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome
Jan 23, 2018: Zealand Pharma to present Phase 2 results on glepaglutide at the ASPEN 2018 Conference in Las Vegas, U.S.
Jan 22, 2018: Shire to Present Data on Short Bowel Syndrome With Intestinal Failure at the ASPEN 2018 Nutrition Science & Practice Conference
Nov 15, 2017: Naia Rare Diseases Announces Clinical Trial Authorization to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome in the United Kingdom
Nov 14, 2017: Recruitment completed in trial to evaluate the optimal dosing frequency for Zealands long-acting GLP-2 analog glepaglutide
Oct 24, 2017: U.S. FDA Grants Orphan Drug Designation to Glepaglutide for the Treatment of Short Bowel Syndrome
Oct 12, 2017: Zealand has initiated a clinical trial to evaluate the potential for less than once-daily dosing with its long-acting GLP-2 analog glepaglutide
Jun 19, 2017: Glepaglutide meets primary endpoint in Phase 2 trial in patients with short bowel syndrome
Feb 06, 2017: Patient recruitment completed for phase II trial with glepaglutide for treatment of short bowel syndrome
Dec 19, 2016: IND submission to initiate clinical trials of NB 1001 (XTEN-GLP1) for treatment of Short Bowel Syndrome announced by Naia Rare Diseases
Nov 29, 2016: Naia Rare Diseases Announces Investigational New Drug Application Submission to Initiate Clinical Trials of NB 1001 for Short Bowel Syndrome
Jul 07, 2016: Shire Receives Extension of Market Authorization in Europe for Revestive (Teduglutide) for the Treatment of Paediatric Patients with Short Bowel Syndrome (SBS)
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Short Bowel Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Number of Products by Stage and Target, H1 2018
Number of Products by Stage and Mechanism of Action, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Short Bowel Syndrome - Pipeline by Adocia SAS, H1 2018
Short Bowel Syndrome - Pipeline by Ardelyx Inc, H1 2018
Short Bowel Syndrome - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018
Short Bowel Syndrome - Pipeline by Naia Ltd, H1 2018
Short Bowel Syndrome - Pipeline by Nutrinia Ltd, H1 2018
Short Bowel Syndrome - Pipeline by OxThera AB, H1 2018
Short Bowel Syndrome - Pipeline by Sancilio & Company Inc, H1 2018
Short Bowel Syndrome - Pipeline by Shire Plc, H1 2018
Short Bowel Syndrome - Pipeline by Tasly Pharmaceutical Group Co Ltd, H1 2018
Short Bowel Syndrome - Pipeline by Zealand Pharma AS, H1 2018
Short Bowel Syndrome - Dormant Projects, H1 2018
Short Bowel Syndrome - Discontinued Products, H1 2018

List of Figures
Number of Products under Development for Short Bowel Syndrome, H1 2018
Number of Products under Development by Companies, H1 2018
Number of Products by Targets, H1 2018
Number of Products by Stage and Targets, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
  • 2018-2023 Global Melanoma Drugs Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Melanoma Drugs market for 2018-2023. Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the mal......
  • 2018-2023 Global Medication Management System Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 139
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Medication Management System market for 2018-2023. Medication management systems ensure tracking and validation of the medication administered to patients at all points of care. These systems help healthcare organizations to minimize medical errors occurring in the healthcare environment. Over the next five years, LPI(LP Information) projects......
  • 2018-2023 Global Drugs for Melanoma Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 137
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Drugs for Melanoma market for 2018-2023. Melanoma is the type of cancer, in which the normal melanin-producing cells called melanocytes are turned into cancerous cells. Melanoma is usually, but not always cancer of the skin and is the most dangerous type of cancer. Mutation in melanin-producing melanocytes leads to uncontrolled division of cells forming the......
  • 2018-2023 Global Membrane Filter Cartridge Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Membrane Filter Cartridge market for 2018-2023. Membrane cartridge filters are typically constructed with a large surface area of thin polymeric filter media, pleated to fit into a relatively small assembly. This results in a filter that offers high flow rates and low pressure losses. These filters are ideal for use in critical applications in the Pharmaceu......
  • 2018-2023 Global Meningococcal Disease Treatment Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 133
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Meningococcal Disease Treatment market for 2018-2023. Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk ......
  • 2018-2023 Global Meningococcal Disease Drugs Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 130
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Meningococcal Disease Drugs market for 2018-2023. Meningococcal disease is a severe infection of meninges, the thin layers of tissue covering brain and spinal cord, caused by the bacteria Neisseria meningitidis. This bacteria can also cause bloodstream infections (septicemia). Bacterial meningitis is severe because of rapid onset and a significant risk of d......
  • 2018-2023 Global Merkel Cell Carcinoma Treatment Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 158
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Merkel Cell Carcinoma Treatment market for 2018-2023. Merkel Cell Carcinoma, a skin malignancy, is caused by the uncontrolled development of Merkel cells in the skin. MCC was originally first described by Toker in 1972. The malady is to a great extent caused by Merkel Cell Polyomavirus (MCV) on parts of the skin in the head, neck and arms, generally occurs ......
  • 2018-2023 Global Microbial Fermentation Technology Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 134
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Microbial Fermentation Technology market for 2018-2023. Fermentation technology is a field which involves the use of microorganisms and enzymes for production of compounds which have application in the energy, material, pharmaceutical, chemical and the food industries. Though fermentation processes are used for generations for the requirement for sustainabl......
  • 2018-2023 Global Culture Media of Microbiology Consumption Market Report
    Published: 15-Oct-2018        Price: US 4660 Onwards        Pages: 137
    In this report, LP Information covers the present scenario (with the base year being 2017) and the growth prospects of global Culture Media of Microbiology market for 2018-2023. A microbiological culture or microbial culture is a process of multiplying microbial organisms. Through allowing them to reproduce in predetermined lifestyle media under controlled laboratory situations. Microbial cultures are used to decide the form of organism, its abundance within the pattern being test......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs